James R. Prudent

Dr. Prudent is the President and CEO of Centrose bringing over 25 years of biotechnology industry experience. Before Centrose, Dr. Prudent served as Chief Scientific Officer and Member of the Board of Directors at EraGen Biosciences and was an essential part of raising over $26 million in equity and grant funds for EraGen. He was responsible for technology and product development in the areas of cancer, infectious disease, cardiology, cystic fibrosis and general life science. Before EraGen, he worked at Third Wave Technologies (now Hologic Inc.) where he co-invented the Invader® Technology. Dr. Prudent was an integral part of transforming Invader into a multi-million dollar product line. Prior to Third Wave, Dr. Prudent worked for IGEN International (acquired by Roche in 2003) where he pioneered new methods of rapidly producing monoclonal antibodies.

He was recipient of the Frost and Sullivan 2005 Product of the Year Award and received the "Biotechnology Industry Organization's 2006 Innovation Award". Dr. Prudent received his Ph.D. in Chemistry at the UC - Berkeley  and his B.S. in Bacteriology and Medical Microbiology at the University of Wisconsin - Madison.


Dave Marshall

Dave Marshall brings over 20 years of broad biotechnology experience to Centrose. Prior to Centrose, he worked at EraGen Biosciences (now Luminex) where he co-invented multiple products for the analysis and detection of diseased genes and infectious organisms. Prior to EraGen, Mr. Marshall worked at Third Wave Technologies (now Hologic) where he helped develop and manufacture the one step Invader Platform. His areas of expertise include; cancer genetics, nucleic acid chemistry, molecular biology, biochemistry, cell culture, animal science and chemoprevention. He graduated from the University of Wisconsin at Madison and is a named inventor on 6 issued US patents and 8 pending US applications.